EUCTR2005-002965-35-FI进行中(未招募)不适用
Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children
Sanofi Pasteur SA0 个研究点目标入组 100 人开始时间: 2005年7月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Aged 6 months to 8 years on the day of inclusion,
- •2) Born at full term of pregnancy (>37 weeks) with a birth weight = 2.5 kg (infants and toddlers [<2 years] only),
- •3) Informed consent form signed by the parent(s) or another legal representative (and by an independent witness if required by local regulations),
- •4) Able to attend all scheduled visits and to comply with all trial procedures,
- •5) Subject who completed vaccination according to the national immunization schedule.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Febrile illness (rectal equivalent temperature = 38.0°C on the day of inclusion),
- •2) Participation in another clinical trial in the four weeks preceding the first trial vaccination,
- •3) Planned participation in another clinical trial during the present trial period,
- •4) Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy,
- •5) Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances,
- •6) Chronic illness at a stage that could interfere with trial conduct or completion,
- •7) Blood or blood-derived products received in the past three months,
- •8) Previous vaccination against influenza with the trial vaccine or another vaccine,
- •9) Any vaccination in the four weeks preceding the first trial vaccination,
- •10) Vaccination planned in the four weeks following the trial vaccinations,
- •11) Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination,
- •12) History of seizures (Infants and toddlers [<2 years] only).
研究者
相似试验
进行中(未招募)
1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2009-2010 Northern Hemisphere Season)Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal routeEUCTR2009-009977-85-FRSanofi Pasteur SA131
进行中(未招募)
1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) - Immunogenicity and Safety of a Vaccine against Influenza (2010-2011 NH season, intramuscular route)Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route.EUCTR2009-017690-38-FRSanofi Pasteur SA129
进行中(未招募)
不适用
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 NH season, intradermal route)EUCTR2009-017688-40-BESanofi Pasteur SA
已完成
2 期
Trial to Describe the Safety and Immunogenicity of Fluzone®InfluenzaNCT00524940Sanofi Pasteur, a Sanofi Company124
进行中(未招募)
1 期
Effictiveness and safety of vaccination with Live-attenuated Influenza VaccineEUCTR2015-003250-41-GBPublic Health England2,500
